Easterly Investment Partners’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.16M | Sell |
48,273
-33,600
| -41% | -$879K | 0.06% | 187 |
|
|
2026
Q1 | $2.27M | Sell |
81,873
-43,555
| -35% | -$1.16M | 0.17% | 84 |
|
|
2025
Q4 | $3.12M | Buy |
125,428
+36,110
| +40% | +$911K | 0.19% | 103 |
|
|
2025
Q3 | $2.28M | Buy |
89,318
+18,600
| +26% | +$459K | 0.15% | 116 |
|
|
2025
Q2 | $1.71M | Buy |
70,718
+50
| +0.1% | +$1.17K | 0.12% | 122 |
|
|
2025
Q1 | $1.79M | Buy |
70,668
+51,168
| +262% | +$1.34M | 0.15% | 118 |
|
|
2024
Q4 | $517K | Buy |
19,500
+200
| +1% | +$5.42K | 0.04% | 171 |
|
|
2024
Q3 | $559K | Hold |
19,300
| – | – | 0.04% | 175 |
|
|
2024
Q2 | $540K | Sell |
19,300
-813
| -4% | -$22.4K | 0.05% | 170 |
|
|
2024
Q1 | $558K | Sell |
20,113
-47,243
| -70% | -$1.31M | 0.04% | 177 |
|
|
2023
Q4 | $1.94M | Sell |
67,356
-338,645
| -83% | -$10.2M | 0.21% | 108 |
|
|
2023
Q3 | $13.5M | Buy |
406,001
+1,295
| +0.3% | +$45.8K | 1.48% | 15 |
|
|
2023
Q2 | $14.8M | Buy |
404,706
+137,180
| +51% | +$5.34M | 1.31% | 21 |
|
|
2023
Q1 | $10.9M | Sell |
267,526
-2,865
| -1% | -$124K | 0.96% | 39 |
|
|
2022
Q4 | $13.9M | Sell |
270,391
-13,334
| -5% | -$639K | 1.2% | 31 |
|
|
2022
Q3 | $12.4M | Sell |
283,725
-205,322
| -42% | -$9.98M | 1.19% | 27 |
|
|
2022
Q2 | $25.6M | Sell |
489,047
-167,487
| -26% | -$8.54M | 2.28% | 4 |
|
|
2022
Q1 | $34M | Buy |
656,534
+349,682
| +114% | +$18.1M | 2.57% | 3 |
|
|
2021
Q4 | $18.1M | Sell |
306,852
-152,233
| -33% | -$7.54M | 1.32% | 24 |
|
|
2021
Q3 | $19.7M | Buy |
459,085
+309,005
| +206% | +$13.7M | 1.34% | 21 |
|
|
2021
Q2 | $5.88M | Sell |
150,080
-445,785
| -75% | -$17.3M | 0.69% | 39 |
|
|
2021
Q1 | $21.6M | Buy |
595,865
+58,936
| +11% | +$2.09M | 2.58% | 20 |
|
|
2020
Q4 | $19.8M | Sell |
536,929
-2,180,284
| -80% | -$80M | 2.73% | 16 |
|
|
2020
Q3 | $94.6M | Buy |
2,717,213
+386,617
| +17% | +$13.6M | 3.75% | 9 |
|
|
2020
Q2 | $72.3M | Sell |
2,330,596
-89,130
| -4% | -$3.03M | 3.28% | 12 |
|
|
2020
Q1 | $74.9M | Buy |
2,419,726
+1,733,096
| +252% | +$59.1M | 3.32% | 15 |
|
|
2019
Q4 | $25.5M | Buy |
686,630
+633,002
| +1,180% | +$22.5M | 0.72% | 38 |
|
|
2019
Q3 | $1.83M | Sell |
53,628
-3,126,595
| -98% | -$114M | 0.05% | 50 |
|
|
2019
Q2 | $131M | Sell |
3,180,223
-2,124,153
| -40% | -$84.3M | 3.28% | 14 |
|
|
2019
Q1 | $214M | Buy |
+5,304,376
| New | +$212M | 5.16% | 3 |
|
Other funds holding PFE
Easterly Investment Partners's PFE Position: Q2 2026 in Review
Easterly Investment Partners reduced its Pfizer (PFE) stake by 41% in Q2 2026, selling an estimated $879K and leaving 48,273 shares worth $1.16M. The position accounts for 0.06% of the portfolio, ranked #187.
Easterly Investment Partners first reported a position in PFE in Q1 2019 and has held it in 30 quarters since. The position peaked at $214M in Q1 2019. 2,831 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Easterly Investment Partners held 48,273 shares of Pfizer worth $1.16M as of Q2 2026.
- Easterly Investment Partners sold 33,600 Pfizer shares in Q2 2026, an estimated $879K.
- Pfizer made up 0.06% of Easterly Investment Partners's portfolio in Q2 2026, its #187 holding.
- Easterly Investment Partners first reported a position in Pfizer in Q1 2019 and has held it in 30 quarters since.
- Easterly Investment Partners's Pfizer position peaked at $214M in Q1 2019.
- 2,831 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Easterly Investment Partners's 13F filing for Q2 2026, filed 23 Jul 2026.